Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study

Ann Oncol. 2022 Jan;33(1):107-108. doi: 10.1016/j.annonc.2021.09.009. Epub 2021 Sep 20.
No abstract available

Publication types

  • Letter
  • Observational Study

MeSH terms

  • BNT162 Vaccine
  • COVID-19*
  • Humans
  • Neoplasms* / drug therapy
  • Prospective Studies
  • RNA, Messenger
  • SARS-CoV-2

Substances

  • RNA, Messenger
  • BNT162 Vaccine